All In Biotech

Free tool

FAERS Monitor: Tafinlar

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217514 or its brand name (Tafinlar, Dabrafenib Mesylate). Reports on generic versions are filed under their own applications.

Reports

21,157

Serious

15,709

74% of reports

Hospitalization

5,907

Death reported

4,427

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pyrexia4,146
  • death2,899
  • malignant neoplasm progression1,771
  • fatigue1,445
  • nausea1,414
  • chills1,343
  • rash1,189
  • vomiting995
  • diarrhoea988
  • headache750
  • asthenia733
  • malaise628
  • decreased appetite592
  • arthralgia590
  • visual impairment550

Reports by year received

View as table
YearReports
20121
2013415
2014730
20151,704
20161,382
20171,636
20182,134
20192,338
20202,056
20212,057
20221,877
20231,774
20241,275
20251,103
2026675

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,033,002 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
malignant neoplasm progressionSignal1,77117.516.727,151
pyrexiaSignal4,14612.011.742,167
chillsSignal1,34311.510.912,800
visual impairmentSignal5504.44.11,458
deathSignal2,8993.43.24,973
rashSignal1,1892.72.61,311
decreased appetiteSignal5922.52.3555
vomitingSignal9952.12.0589
asthenia7331.91.8338
fatigue1,4451.81.8581
nausea1,4141.81.7498
diarrhoea9881.51.4182
malaise6281.41.380
arthralgia5901.41.372
headache7501.21.123

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.